Cidara Therapeutics, Inc.

CDTX

US1717572069

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 16:48:49 16/07/2024 BST			5-day change	1st Jan Change
12.72 ^USD	+1.76%		+10.37%	-19.90%

07-01	Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell Microcap Value Index	CI
07-01	Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 3000E Value Index	CI

Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell Microcap Value Index

July 30, 2024

Latest news about Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell Microcap Value Index	06-30	CI
Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 3000E Value Index	06-30	CI
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q1 Revenue $8.5M	05-15	MT
Cidara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Top Premarket Gainers	04-25	MT
North American Morning Briefing : More Tech -2-	04-25	DJ
North American Morning Briefing : More Tech Earnings in Focus With GDP Data Adding to the Uncertainty	04-25	DJ
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset	04-24	DJ
Transcript : Cidara Therapeutics, Inc. - Special Call	04-24
Cidara Therapeutics, Inc. Announces Board Changes	04-24	CI
Mundipharma International Limited acquired All assets and rights related to REZZAYO of Cidara Therapeutics, Inc..	04-23	CI
Cidara Therapeutics, Inc. announced that it has received $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors	04-23	CI
Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket	04-23	MT
Cidara Therapeutics, Inc. announced that it expects to receive $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors	04-22	CI
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q4 Revenue $17.6M	04-22	MT
Cidara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04-22	CI
Cidara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-22	CI
Cidara Therapeutics to Effect 1-for-20 Reverse Stock Split	04-22	MT
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	04-11	DJ
North American Morning Briefing : Focus Turns to -2-	04-04	DJ
North American Morning Briefing : Stocks Set for -2-	03-28	DJ
North American Morning Briefing : Microsoft Kicks Off Big Tech Bonanza	01-30	DJ
Cidara Therapeutics Says UK Regulator Approved Invasive Candidiasis Treatment	01-30	MT
Cidara Therapeutics, Inc. Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults	01-29	CI
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China	12-06	CI

Chart Cidara Therapeutics, Inc.

Duration

Period

More charts

Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Companyâs portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.

Sector

Biotechnology & Medical Research

Calendar

18/07/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Cidara Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.5 USD

Average target price

25 USD

Spread / Average Target

+100.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CIDARA THERAPEUTICS, INC.	-19.90%	57.02M
VERTEX PHARMACEUTICALS INCORPORATED	+20.58%	127B
REGENERON PHARMACEUTICALS, INC.	+24.23%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-18.57%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-16.13%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+12.73%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+56.65%	14.43B

Bio Therapeutic Drugs